216574-51-5Relevant academic research and scientific papers
RAF KINASE INHIBITORS
-
Page/Page column 11; 18, (2008/12/06)
Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
Inhibition of p38 kinase activity by aryl ureas
-
, (2008/06/13)
This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases other than cancer and proteolytic enzyme mediated diseases other than cancer, and pharmaceutical compositions for use in such therapy.
p38 kinase inhibitors for the treatment of arthritis and osteoporosis: Thienyl, furyl, and pyrrolyl ureas
Redman, Aniko M,Johnson, Jeffrey S.,Dally, Robert,Swartz, Steve,Wild, Hanno,Paulsen, Holger,Caringal, Yolanda,Gunn, David,Renick, Joel,Osterhout, Martin,Kingery-Wood, Jill,Smith, Roger A.,Lee, Wendy,Dumas, Jacques,Wilhelm, Scott M.,Housley, Timothy J.,Bhargava, Ajay,Ranges, Gerald E.,Shrikhande, Alka,Young, Deborah,Bombara, Michael,Scott, William J.
, p. 9 - 12 (2007/10/03)
Inhibitors of the MAP kinase p38 are potentially useful for the treatment for osteoporosis, arthritis, and other inflammatory diseases. A series of thienyl, furyl, and pyrrolyl ureas has been identified as potent p38 inhibitors, displaying in vitro activity in the nanomolar range. (C) 2000 Elsevier Science Ltd.
